PTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Proteostasis Therapeutics's Enterprise Value is $2.90 Mil. Proteostasis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-40.81 Mil. Therefore, Proteostasis Therapeutics's EV-to-EBIT for today is -0.07.
The historical rank and industry rank for Proteostasis Therapeutics's EV-to-EBIT or its related term are showing as below:
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Proteostasis Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $1,119.93 Mil. Proteostasis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-40.81 Mil. Proteostasis Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -3.64%.
The historical data trend for Proteostasis Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteostasis Therapeutics Annual Data | ||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
EV-to-EBIT | Get a 7-Day Free Trial | - | -161.38 | -65.68 | -50.46 | -37.94 |
Proteostasis Therapeutics Quarterly Data | ||||||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
EV-to-EBIT | Get a 7-Day Free Trial | -12.35 | -37.94 | -20.24 | -30.64 | -27.44 |
For the Biotechnology subindustry, Proteostasis Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Proteostasis Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Proteostasis Therapeutics's EV-to-EBIT falls into.
Proteostasis Therapeutics's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 2.900 | / | -40.812 | |
= | -0.07 |
Proteostasis Therapeutics's current Enterprise Value is $2.90 Mil.
Proteostasis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteostasis Therapeutics (NAS:PTI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Proteostasis Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Sep. 2020 ) | = | EBIT | / | Enterprise Value (Q: Sep. 2020 ) |
= | -40.812 | / | 1119.9258 | |
= | -3.64 % |
Proteostasis Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $1,119.93 Mil.
Proteostasis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Proteostasis Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Franklin M Berger | director | 1000 MARINA BLVD, STE 200, BRISBANE CA 94005 |
Badrul A. Chowdhury | director | PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135 |
Kimberlee C Drapkin | director | PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Jeffrey W. Kelly | director | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Emmanuel Dulac | director | PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135 |
David Arkowitz | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Michael Alfieri | officer: Interim Head of Finance | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Greffrey S. Gilmartin | officer: Chief Medical Officer | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Meenu Chhabra | director, officer: President and CEO | C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
Sheila Wilson | officer: Chief Operating Officer | C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135 |
Benito Munoz | officer: Chief Scientific Officer | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Eric D Larson | officer: See Remarks | C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641 |
Marija Zecevic | officer: Chief Commercial Officer | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
New Enterprise Associates 12, Limited Partnership | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Peter J Barris | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By PRNewswire PRNewswire • 01-22-2020
By Business Wire Business Wire • 08-25-2020
By Marketwired Marketwired • 12-15-2020
By PRNewswire PRNewswire • 08-26-2020
By PRNewswire PRNewswire • 09-15-2020
By PRNewswire PRNewswire • 03-11-2020
By Marketwired Marketwired • 09-16-2020
By PRNewswire PRNewswire • 08-24-2020
By PRNewswire PRNewswire • 08-28-2020
By PRNewswire PRNewswire • 08-07-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.